INMB
Price
$2.23
Change
-$0.13 (-5.51%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
64.29M
20 days until earnings call
MEIP
Price
$2.68
Change
+$0.08 (+3.08%)
Updated
Jul 10, 04:35 PM (EDT)
Capitalization
18.32M
Interact to see
Advertisement

INMB vs MEIP

Header iconINMB vs MEIP Comparison
Open Charts INMB vs MEIPBanner chart's image
INmune Bio
Price$2.23
Change-$0.13 (-5.51%)
Volume$15.79K
Capitalization64.29M
MEI Pharma
Price$2.68
Change+$0.08 (+3.08%)
Volume$100
Capitalization18.32M
INMB vs MEIP Comparison Chart in %
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. MEIP commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and MEIP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (INMB: $2.36 vs. MEIP: $2.75)
Brand notoriety: INMB and MEIP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 60% vs. MEIP: 32%
Market capitalization -- INMB: $64.29M vs. MEIP: $18.32M
INMB [@Biotechnology] is valued at $64.29M. MEIP’s [@Biotechnology] market capitalization is $18.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileMEIP’s FA Score has 0 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • MEIP’s FA Score: 0 green, 5 red.
According to our system of comparison, MEIP is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 5 TA indicator(s) are bullish while MEIP’s TA Score has 5 bullish TA indicator(s).

  • INMB’s TA Score: 5 bullish, 5 bearish.
  • MEIP’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MEIP is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а 0.00% price change this week, while MEIP (@Biotechnology) price change was +14.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

INMB is expected to report earnings on Oct 29, 2025.

MEIP is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INMB($64.3M) has a higher market cap than MEIP($18.3M). MEIP YTD gains are higher at: 11.789 vs. INMB (-49.465). MEIP has higher annual earnings (EBITDA): -22.17M vs. INMB (-41.52M). MEIP has more cash in the bank: 20.5M vs. INMB (19.3M). INMB has less debt than MEIP: INMB (347K) vs MEIP (11.7M). INMB has higher revenues than MEIP: INMB (50K) vs MEIP (0).
INMBMEIPINMB / MEIP
Capitalization64.3M18.3M351%
EBITDA-41.52M-22.17M187%
Gain YTD-49.46511.789-420%
P/E RatioN/A1.09-
Revenue50K0-
Total Cash19.3M20.5M94%
Total Debt347K11.7M3%
FUNDAMENTALS RATINGS
INMB vs MEIP: Fundamental Ratings
INMB
MEIP
OUTLOOK RATING
1..100
5014
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
9844
P/E GROWTH RATING
1..100
10044
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEIP's Valuation (56) in the Pharmaceuticals Other industry is in the same range as INMB (81) in the Biotechnology industry. This means that MEIP’s stock grew similarly to INMB’s over the last 12 months.

MEIP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as INMB (100) in the Biotechnology industry. This means that MEIP’s stock grew similarly to INMB’s over the last 12 months.

MEIP's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as INMB (99) in the Biotechnology industry. This means that MEIP’s stock grew similarly to INMB’s over the last 12 months.

MEIP's Price Growth Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for INMB (98) in the Biotechnology industry. This means that MEIP’s stock grew somewhat faster than INMB’s over the last 12 months.

MEIP's P/E Growth Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for INMB (100) in the Biotechnology industry. This means that MEIP’s stock grew somewhat faster than INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBMEIP
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 8 days ago
72%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
62%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APAAF0.100.01
+10.40%
APPIA RARE EARTHS & URANIUM CORP.
YUEIF1.59N/A
N/A
Yue Yuen Industrial (Holdings) Ltd
FCCTP12.06N/A
N/A
First Community Corp. (TN)
SHTDY11.68-0.01
-0.04%
Sinopharm Group Co. Ltd.
RMLFF0.81N/A
-0.61%
Rusoro Mining Ltd.

INMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with UBX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then UBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
+2.61%
UBX - INMB
51%
Loosely correlated
N/A
ORMP - INMB
38%
Loosely correlated
+3.83%
ABCL - INMB
38%
Loosely correlated
+8.48%
AXON - INMB
37%
Loosely correlated
+1.98%
PROK - INMB
35%
Loosely correlated
+16.35%
More

MEIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEIP has been loosely correlated with GOSS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MEIP jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEIP
1D Price
Change %
MEIP100%
+5.77%
GOSS - MEIP
45%
Loosely correlated
+7.09%
DNLI - MEIP
29%
Poorly correlated
+4.68%
AXON - MEIP
28%
Poorly correlated
+1.98%
INMB - MEIP
27%
Poorly correlated
+2.61%
NRIX - MEIP
27%
Poorly correlated
+7.94%
More